Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S. Montalban-Bravo G, et al. Among authors: kantarjian h. Cell Rep Med. 2024 Jun 18;5(6):101585. doi: 10.1016/j.xcrm.2024.101585. Epub 2024 May 22. Cell Rep Med. 2024. PMID: 38781960 Free PMC article.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: kantarjian hm. Blood. 2024 Jul 4;144(1):61-73. doi: 10.1182/blood.2024023930. Blood. 2024. PMID: 38551807
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: kantarjian h. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Roboz GJ, Sanz G, Griffiths EA, Yee K, Kantarjian H, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illés Á, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell CL, Hao Y, Keer HN, Azab M, Döhner H. Roboz GJ, et al. Among authors: kantarjian h. Blood Adv. 2024 Apr 23;8(8):2020-2029. doi: 10.1182/bloodadvances.2023012062. Blood Adv. 2024. PMID: 38231126 Free PMC article. Clinical Trial.
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Short NJ, et al. Among authors: kantarjian h. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e168-e173. doi: 10.1016/j.clml.2023.12.016. Epub 2023 Dec 30. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38212207
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. Among authors: kantarjian h. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation.
Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM. Senapati J, et al. Among authors: kantarjian hm. Am J Hematol. 2025 Feb;100(2):249-259. doi: 10.1002/ajh.27561. Epub 2024 Dec 24. Am J Hematol. 2025. PMID: 39718824
Artificial Intelligence Assessment of Chest Radiographs for COVID-19.
Sasaki K, Garcia-Manero G, Nigo M, Jabbour E, Ravandi F, Wierda WG, Jain N, Takahashi K, Montalban-Bravo G, Daver NG, Thompson PA, Pemmaraju N, Kontoyiannis DP, Sato J, Karimaghaei S, Soltysiak KA, Raad II, Kantarjian HM, Carter BW; D3CODE Research Team. Sasaki K, et al. Among authors: kantarjian hm. Clin Lymphoma Myeloma Leuk. 2024 Nov 29:S2152-2650(24)02435-2. doi: 10.1016/j.clml.2024.11.013. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39710565
2,547 results